WHAT HAPPENS TO MEDICAL CANNABIS PROGRAMS UNDER MCCA?
The OMC will work in partnership with state regulators to issue Schedule VI permits to existing, licensed medical cannabis businesses. This ensures patients maintain access while states and the federal government coordinate efforts to improve safety, consistency, and access. Companies with dual licensing will have the option of serving the state adult-use market or getting a Schedule VI permit and serving a national patient market. Permitted dispensaries will qualify for Schedule Vl specialty pharmacy license.
For patients and medical professionals, the enrollment protocols in each state will remain in place as the OMC develops protocols for something that looks more like a prescription. However, the protections associated with the ID card will be national and now fall under the Americans with Disabilities Act (ADA). They can also choose products from a national marketplace.
After all the “hemp-derived” companies and state-licensed producers opt in, the OMC will evaluate what additional licensing is needed to serve the national patient population and research needs. The OMC will then begin issuing Schedule VI licenses, transitioning from a state-by-state program to a national one.
As cannabis medicines integrate into U.S. healthcare, patients and healthcare providers will benefit from standardized product protocols, including labeling, testing, and product standardization.
Nothing in the MCCA precludes product manufacturers from seeking FDA approval through traditional drug development pathways.
WHAT HAPPENS TO ADULT USE PROGRAMS UNDER MCCA?
Nothing directly. However, MCCA does decriminalize cannabis. (This is not a leading/public talking point at this time.)
Share this page
